Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2021)
15 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 19, 2021
Slide 1: Proxy Season Update April 2021
Proxy Season Update April 2021
Slide 2: Our mission
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases 2 Our mission
Slide 3: 2020 A Year of Strong Performance
2020 A Year of Strong Performance Continued to strengthen our diversified portfolio with leading positions in Oncology, Hematology, Immunology and CardiovascularA 63% increase in total revenues, or 7%* on a pro forma basisStrengthened the company with important business development transactions, inc
Slide 4: Company Response to COVID-19
Company Response to COVID-19 4 Expanded patient support programs to help eligible unemployed patients in the USExpanded access to free BMS medicines, including some of our most widely prescribed products and those prescribed via telehealth servicesMaintained uninterrupted supply of medicines to pati
Slide 5: Our Commitment to Sustainability & Diversity and Inclusion
Our Commitment to Sustainability & Diversity and Inclusion Our approach to sustainability is global and encompasses the products we make, how we make them, access to our medicines, our facilities, our people and our communitiesWe conduct our business in ways that contribute to economic opportunity,
Slide 6: Environmental Progress Made in 2020
Environmental Progress Made in 2020* 6 20.7%Reduction inGHG emissions Reduced energyconsumed13.3% 10.8%Less water used Increased EV/hybrid in fleet19.2% Reduce wastegenerated59.1% 300%Increase in recycled/reclaimed efforts *Figures shown in infographic are 2019 metrics against 2015 baseline.(does no
Slide 7: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance 7 Board Accountability and Shareholder Rights Regular shareholder engagementAnnual election of DirectorsMajority voting standard for election of DirectorsRobust Lead Independent Director roleLimit on public company board memberships for BMS Directors (4)Limit
Slide 8: Board Well Equipped to Support Company Strategies
Giovanni Caforio, M.D. More than 19 years of experience at Bristol-Myers Squibb, including previous role as COO Board Well Equipped to Support Company Strategies 8 Karen Vousden, Ph.D. Chief Scientist at Cancer Research UK Senior Group Leader at the Francis Crick Institute in LondonFormer Director,
Slide 9: Executive Compensation Supporting our Strategy
90% performance-based Executive Compensation Supporting our Strategy Continued Commitment to our Compensation Philosophy and Structure Pay for PerformanceA substantial proportion of our executives’ pay is variable, at-risk based on our financial and operational results and delivered in the form of e
Slide 10: 2020 Compensation Plan
2020 Compensation Plan 10 *Items outlined with dotted line are updates to the 2020 Compensation Program Base Salary Annual Incentive (Paid in cash) Allows us to attract and retain talent in a highly competitive labor marketBased on specialized qualifications, experience and role impact, and pay leve
Slide 11: We Value Your Support at Our 2021 Annual Meeting
We Value Your Support at Our 2021 Annual Meeting 11 FOR Election of Directors FOR Advisory Vote to Approve the Compensation of our Named Executive Officers FOR Approval of the Company’s 2021 Stock Award and Incentive Plan FOR Approval of the Appointment of an Independent Registered Public Accou
Slide 12: We Value Your Support at Our 2021 Annual Meeting (continued)
We Value Your Support at Our 2021 Annual Meeting (continued) 12 Management Proposal on the Approval ofCompany’s 2021 Stock Award and Incentive Plan The 2021 Plan is an “omnibus” plan, authorizing a variety of equity award types as well as cash incentive awards. The 2021 Plan is similar in scope to o
Slide 13: We Value Your Support at Our 2021 Annual Meeting (continued)
We Value Your Support at Our 2021 Annual Meeting (continued) 13 Shareholder Proposal on the Adoption of a Board policy that the Chairperson of the Board be an Independent Director After careful consideration, the Board did not feel that this proposal deserved its support. The Board believes differen
Slide 14: We Value Your Support at Our 2021 Annual Meeting (continued)
We Value Your Support at Our 2021 Annual Meeting (continued) 14 The company is committed to high standards of corporate governance, including taking steps to achieve greater transparency and accountability to our shareholders. As such, at this Annual Meeting, the Board is asking shareholders to appr
Slide 15: Forward-Looking Information and Non-GAAP Financial Information
Forward-Looking Information and Non-GAAP Financial Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual
Bristol Myers Squibb — Shareholder Meeting (April 2021) on 6ix